These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20521434)

  • 21. Aspirin in primary prevention of cardiovascular disease in the elderly.
    Galli M; Andreotti F; D'Amario D; Vergallo R; Montone RA; Porto I; Crea F
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):326-327. PubMed ID: 31504373
    [No Abstract]   [Full Text] [Related]  

  • 22. Accrual and drop out in a primary prevention randomised controlled trial: qualitative study.
    Eborall HC; Stewart MC; Cunningham-Burley S; Price JF; Fowkes FG
    Trials; 2011 Jan; 12():7. PubMed ID: 21223551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin for primary prevention of cardiovascular disease events.
    Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
    Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
    U.S. Preventive Services Task Force
    Am J Nurs; 2002 Mar; 102(3):67, 69-70. PubMed ID: 11976531
    [No Abstract]   [Full Text] [Related]  

  • 26. Aspirin for primary prevention of cardiovascular disease in women.
    Jneid H
    Methodist Debakey Cardiovasc J; 2010 Nov-2011 Jan; 6(4):37-42. PubMed ID: 21088658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
    Noubiap JJ; Nansseu JR
    Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
    Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
    Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association(AHA), and an expert consensus document of the American College of Cardiology Foundation (ACCF). Diabetes Care, 33:6; June 2010; 1395-1402.
    Gilpin VL; ; ;
    J Vasc Nurs; 2010 Dec; 28(4):154-5. PubMed ID: 21074118
    [No Abstract]   [Full Text] [Related]  

  • 30. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
    Mora S; Ames JM; Manson JE
    JAMA; 2016 Aug; 316(7):709-10. PubMed ID: 27323335
    [No Abstract]   [Full Text] [Related]  

  • 32. Aspirin for primary prevention: do potential benefits outweigh the risks?
    Shakib S
    Intern Med J; 2009 Jun; 39(6):401-7. PubMed ID: 19580619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
    Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
    J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers, atherosclerosis and cardiovascular events.
    Rosenson RS
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):619-22. PubMed ID: 18510479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The case against routine aspirin use for primary prevention in low-risk adults.
    Bailey AL; Smyth SS; Campbell CL
    Am Fam Physician; 2011 Jun; 83(12):1387-90. PubMed ID: 21671539
    [No Abstract]   [Full Text] [Related]  

  • 36. [Primary prevention of cardiovascular disease].
    Gohlke H
    Dtsch Med Wochenschr; 2005 Jan; 130(1-2):38-43. PubMed ID: 15619173
    [No Abstract]   [Full Text] [Related]  

  • 37. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antiaggregation: aspirin].
    Eichenberger A; Pontiggia L; Beer JH
    Ther Umsch; 2003 Jan; 60(1):15-8. PubMed ID: 12638472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.